This treatment was an absolute godsend
Each year, tens of thousands of men in England receive a prostate cancer diagnosis and face weeks of repeated treatment that quietly erodes their daily lives. The NHS has now begun offering a precision radiotherapy technique — SABR — that condenses twenty sessions into five, directing radiation with enough accuracy to spare healthy tissue and hasten recovery. It is a moment where medical capability and human dignity converge, offering men not just a treatment, but a faster return to the lives they were living before the diagnosis arrived.
- For years, men with prostate cancer endured 20 radiotherapy sessions spread across weeks, accumulating fatigue and disruption that compounded an already difficult diagnosis.
- SABR technology now focuses powerful radiation precisely onto tumors, dramatically reducing collateral damage to surrounding tissue and cutting treatment to just five sessions.
- Around 3,500 men annually are expected to choose this option across 48 NHS radiotherapy centres beginning this month, marking the first time SABR is offered to prostate cancer patients outside clinical trials.
- One patient, 70-year-old Edwin Lambert, completed treatment and was well enough to join an archaeological dig within five weeks — calling the experience 'an absolute godsend.'
- Trials are already underway for high-risk prostate cancer patients, raising the possibility that SABR's reach will eventually extend well beyond the current eligible population.
The NHS is rolling out a faster, more targeted approach to treating prostate cancer across England. Men diagnosed with low- or intermediate-risk prostate cancer can now access stereotactic ablative radiotherapy — SABR — which compresses a traditional 20-session course of treatment into just five visits. Of the roughly 17,500 men annually who fall into these risk categories, modelling suggests around 3,500 will choose this new path, while others will continue with active monitoring where the disease moves slowly enough to warrant a watch-and-wait approach.
What distinguishes SABR is its precision. Rather than exposing a broad area to repeated doses of radiation over weeks, the technique concentrates a powerful beam directly onto the tumor, limiting damage to surrounding healthy tissue. Prof Peter Johnson, the NHS national clinical director for cancer, noted that this allows men to return to normal life far more quickly. All 48 radiotherapy centres across England are expected to offer the treatment within weeks. Though SABR has previously been used for lung and brain cancers, this marks its first availability to prostate cancer patients outside of clinical trials.
Edwin Lambert, a 70-year-old from Suffolk, lived the contrast firsthand. After hormone therapy brought difficult side effects, he moved on to precision radiotherapy targeting his prostate and nearby lymph nodes. Watching other men endure the traditional 20-session regimen during his own visits, he was struck by the visible toll it took. His own recovery was swift enough that within five weeks he was participating in an archaeological dig he had long anticipated.
Prostate Cancer UK welcomed the rollout as a meaningful reduction in the burden cancer places on patients and families, and expressed hope that accumulating trial evidence will eventually extend SABR's reach to high-risk patients as well. For now, the expansion trades weeks of treatment for days — and in doing so, returns a measure of ordinary life to the men who need it most.
The National Health Service is rolling out a faster, more targeted way to treat prostate cancer across England. Beginning this month, thousands of men diagnosed with low- or intermediate-risk prostate cancer will have access to a precision radiotherapy technique called SABR—stereotactic ablative radiotherapy—that compresses what used to take 20 treatment sessions into just five.
The shift represents a significant change in how the NHS approaches this disease. Each year, roughly 55,000 men in England receive a prostate cancer diagnosis. Of those, about 17,500 fall into the low- or intermediate-risk categories, meaning their cancers are slower-growing and less immediately aggressive. Modelling suggests around 3,500 of these men will choose this new form of treatment, though some will continue to opt for active monitoring—a watch-and-wait approach that makes sense when the disease moves slowly enough that it may never cause serious harm.
What makes SABR different is precision. The technique focuses a powerful beam of radiation directly onto the tumor while sparing surrounding healthy tissue from unnecessary exposure. This targeted approach reduces the collateral damage that comes with traditional radiotherapy, which requires repeated visits over weeks and affects a broader area. Prof Peter Johnson, the national clinical director for cancer, explained that the concentrated delivery allows men to return to normal life far more quickly than they would with conventional treatment. All 48 radiotherapy centres across the country are expected to begin offering SABR within weeks.
The treatment is not entirely new to the NHS. It has already been used for patients with lung cancer and brain cancer. This marks the first time, however, that it is being offered to prostate cancer patients outside of clinical trials. Trials are currently underway to determine whether SABR can safely and effectively treat high-risk prostate cancer patients as well, which could eventually expand access even further.
Edwin Lambert, a 70-year-old from Suffolk, experienced both sides of this equation. Diagnosed with prostate cancer in January 2025, he initially underwent hormone therapy, which brought its own set of side effects: loss of libido, hot flushes, mood swings, and fatigue. When he moved on to the precision radiotherapy—targeting his prostate and the lymph nodes nearby—he found it considerably more manageable. During his hospital visits, he observed men undergoing the traditional 20-session radiotherapy regimen and was struck by how much the repeated treatments seemed to wear them down. His own experience included increased urination during and shortly after treatment, but within five weeks he was well enough to participate in an archaeological dig he had long been planning. He described the treatment as "an absolute godsend."
Amy Rylance of Prostate Cancer UK called the rollout wonderful news, noting that it would significantly reduce the burden cancer places on patients and their families. The charity is already looking ahead, hopeful that SABR will eventually become available to even more prostate cancer patients as evidence from ongoing trials accumulates. For now, the expansion represents a meaningful step forward for a substantial portion of men facing this diagnosis—one that trades weeks of treatment for days, and reduces the physical toll in the process.
Notable Quotes
This technology lets us focus a powerful and precise beam of radiotherapy directly on to the cancer, limiting the damage to healthy cells, and the fact it can be delivered in 15 fewer doses will help men get back to living their lives far more quickly.— Prof Peter Johnson, national clinical director for cancer
It will massively reduce the burden that cancer places on them, and their loved ones.— Amy Rylance, Prostate Cancer UK
The Hearth Conversation Another angle on the story
Why does compressing 20 sessions into five matter so much? Isn't the total radiation dose the same?
The dose is concentrated and precisely aimed, so healthy tissue gets spared. But the real difference is in living your life. Twenty sessions means four weeks of hospital visits, side effects piling up, fatigue accumulating. Five sessions means you're done in a week or two. That's the difference between cancer dominating your schedule and it being a brief interruption.
You mentioned some men choose active monitoring instead. Why would anyone skip treatment if they could have it?
Because low-risk prostate cancer grows so slowly that many men will die of something else entirely before the cancer causes them harm. Treatment itself carries side effects—sexual dysfunction, urinary problems, fatigue. If your cancer might never hurt you, why endure that? SABR changes the calculus a bit because it's faster and gentler, but the choice still makes sense for some.
The patient in the story, Edwin Lambert, had hormone therapy first. Why not go straight to radiotherapy?
Hormone therapy and radiotherapy are different tools for different situations. Sometimes they're used together, sometimes sequentially. In his case, the hormone therapy came first, but the side effects were significant enough that switching to radiotherapy made sense. He tolerated the precision version much better.
What happens to the men who don't choose SABR? Do they get the old treatment?
Yes. This isn't replacing the standard radiotherapy—it's offering an alternative to the roughly 3,500 men who are eligible and interested. The traditional 20-session approach will still be available for those who need it or prefer it. SABR is an option, not a mandate.
The article mentions trials for high-risk patients. How long until that becomes standard?
That's still uncertain. Trials take time to generate solid evidence. But the fact that they're already underway suggests the NHS sees promise. If the data holds up, you could see SABR offered more broadly within a few years.